Breakthrough in HIV treatment: NMN shows promise in reducing CD4+ T cell activation

Roche has inked a new deal with Dyno Ther­a­peu­tics to de­vel­op next-gen­er­a­tion AAV cap­sids for gene ther­a­pies tar­get­ing neu­ro­log­i­cal dis­eases, ex­pand­ing the scope of an

Aspaveli, known as Empaveli in the US, is approved there for the treatment of adults with PNH. Credit: swiftsciencewriting from Pixabay. Sobi has received approval